Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,166,815 papers from all fields of science
Search
Sign In
Create Free Account
NSC 651016
Known as:
NSC-651016
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Naphthalenesulfonates
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2004
Review
2004
New advances in HIV entry inhibitors development.
S. Rusconi
,
A. Scozzafava
,
A. Mastrolorenzo
,
C. Supuran
Current Drug Targets - Infectious Disorders
2004
Corpus ID: 29434081
Considerable advances have been made in the last years in the design of derivatives acting as inhibitors of HIV entry and fusion…
Expand
2002
2002
Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha.
G. P. Schneider
,
R. Salcedo
,
H. Dong
,
H. Kleinman
,
J. Oppenheim
,
O. Howard
Clinical Cancer Research
2002
Corpus ID: 33351046
CXCL12 (stromal cell-derived factor 1alpha), a ligand for CXCR4, has been shown to induce endothelial cell chemotaxis and to…
Expand
2002
2002
Suradista NSC 651016 Inhibits the Angiogenic Activity of CXCL12-Stromal Cell-derived Factor 1 (cid:1) 1
G. P. Schneider
,
R. Salcedo
,
H. Dong
,
H. Kleinman
,
J. Oppenheim
,
O. Howard
2002
Corpus ID: 8180173
CXCL12 (stromal cell-derived factor 1 (cid:1) ), a ligand for CXCR4, has been shown to induce endothelial cell chemotaxis and to…
Expand
Review
1998
Review
1998
Small molecule inhibitor of HIV‐1 cell fusion blocks chemokine receptor‐mediated function
O. Howard
,
T. Korte
,
+6 authors
J. Oppenheim
Journal of Leukocyte Biology
1998
Corpus ID: 25727968
The intersection of the HIV and the chemokine fields began with the observation that HIV entry into cells could be blocked by…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE